ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Total current liabilities

HEALIOS K.K. (4593)

Market cap
¥49.5B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal current liabilities (Million JPY)YoY (%)
Dec 31, 20253,224-3.76%
Dec 31, 20243,350-35.19%
Dec 31, 20235,169+35.74%
Dec 31, 20223,808-36.97%
Dec 31, 20216,042+124.94%
Dec 31, 20202,686+349.92%
Dec 31, 2019597-63.22%
Dec 31, 20181,623+24.78%
Dec 31, 20171,301+68.43%
Dec 31, 2016772-28.53%
Dec 31, 20151,081+127.04%
Dec 31, 2014476

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat